Castle Biosciences CEO sells 14,496 shares
The company's president and chief executive officer reported sales at a weighted-average $35.566 per share under a Rule 10b5-1 plan adopted June 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Castle Biosciences Inc. CEO Derek J. Maetzold exercised 8,165 fully vested options at $2.39 per share for 8,165 common shares on October 5, 2026. Transactions included sales of 14,496 shares at a weighted-average $35.566 per share under a Rule 10b5-1 plan adopted June 2, 2026: 8,580 directly held by Maetzold, 3,198 held by The Maetzold Descendants 2020 Trust, and 2,718 by Derek Maetzold 2020 Irrevocable Trust. Those trusts reported 8,038 and 6,832 shares remaining, respectively.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
13 txns
Insider
MAETZOLD DEREK J
Role
Pres. & Chief Exec. Officer
Sold
14,496 shs ($516K)
Approx. gross sale proceeds
$516K
Approx. exercise cost
$20K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F1, F13 | 8,165 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,165 | $2.39 | $20K |
| Sale | Common Stock F1, F2 | 8,580 | $35.566 | $305K |
| Sale | Common Stock F1, F2, F3 | 3,198 | $35.566 | $114K |
| Sale | Common Stock F1, F2, F4 | 2,718 | $35.566 | $97K |
| holding | Common Stock F5 | -- | -- | -- |
| holding | Common Stock F6 | -- | -- | -- |
| holding | Common Stock F7 | -- | -- | -- |
| holding | Common Stock F8 | -- | -- | -- |
| holding | Common Stock F9 | -- | -- | -- |
| holding | Common Stock F10 | -- | -- | -- |
| holding | Common Stock F11 | -- | -- | -- |
| holding | Common Stock F12 | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 0 contracts (Direct);
Common Stock — 21,064 shares (Direct);
Common Stock — 8,038 shares (Indirect, By The Maetzold Descendants 2020 Trust);
Common Stock — 6,832 shares (Indirect, By Derek Maetzold 2020 Irrevocable Trust);
Common Stock — 11,256 shares (Indirect, By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk);
Common Stock — 11,256 shares (Indirect, By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold);
Common Stock — 11,256 shares (Indirect, By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold);
Common Stock — 11,256 shares (Indirect, By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold);
Common Stock — 11,963 shares (Indirect, By DJM Grantor Retained Annuity Trust No. 6);
Common Stock — 27,862 shares (Indirect, By DJM Grantor Retained Annuity Trust No. 7);
Common Stock — 40,935 shares (Indirect, By DJM Grantor Retained Annuity Trust No. 8);
Common Stock — 23,216 shares (Indirect, DJM Grantor Retained Annuity Trust No. 9)
Footnotes (13)
- F1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
- F2. This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
- F4. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
- F5. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
- F6. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F7. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F8. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F9. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
- F10. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
- F11. Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
- F12. Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
- F13. The shares subject to the option are fully vested.
Key Figures
Options exercised: 8,165 options
Option exercise price: $2.39 per share
Shares sold: 14,496 shares
+4 more
7 metrics
Options exercised
8,165 options
October 5, 2026
Option exercise price
$2.39 per share
Exercise on October 5, 2026
Shares sold
14,496 shares
October 5, 2026
Weighted-average sale price
$35.566 per share
Sales on October 5, 2026
Sale execution price range
$35.310 to $35.965 per share
Multiple trades; inclusive
Shares remaining in The Maetzold Descendants 2020 Trust
8,038 shares
Following the reported sale
Shares remaining in Derek Maetzold 2020 Irrevocable Trust
6,832 shares
Following the reported sale
Key Terms
Rule 10b5-1 plan, weighted-average sale price, fully vested, exercise price, +1 more
5 terms
Rule 10b5-1 plan regulatory
"pursuant to a Rule 10b5-1 plan adopted"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted-average sale price financial
"reflects the weighted-average sale price"
fully vested financial
"The shares subject to the option are fully vested"
exercise price financial
"at $2.3900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grantor Retained Annuity Trust financial
"Held by DJM Grantor Retained Annuity Trust No. 6"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did Castle Biosciences' CEO exercise?
Derek J. Maetzold exercised 8,165 fully vested options at $2.39 per share on October 5, 2026, acquiring 8,165 common shares. The reported option expiration date was May 9, 2028.
What trading prices made up the CSTL CEO's reported sale price?
The sales were executed in multiple trades at prices ranging from $35.310 to $35.965 per share, inclusive. The reported weighted-average sale price was $35.566 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
